All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
16Mar20 16:42 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
03Mar20 07:00 RNS-R Scancell 0.00% Health £23.3m Scancell to Present at Three Research Conferences
03Feb20 07:00 RNS Scancell 0.00% Health £23.3m SCIB1 IND Application Approved
31Jan20 07:00 RNS Scancell 0.00% Health £23.3m Interim Results
20Jan20 07:00 RNS Scancell 0.00% Health £23.3m Third agreement signed for antibody platform
17Dec19 12:44 RNS Scancell 0.00% Health £23.3m Director's Dealings
16Dec19 07:00 RNS Scancell 0.00% Health £23.3m Second agreement signed for AvidiMab platform
20Nov19 07:00 RNS Scancell 0.00% Health £23.3m New European Moditope patent allowed for grant
23Oct19 07:00 RNS Scancell 0.00% Health £23.3m Directorate Change
26Sep19 07:00 RNS Scancell 0.00% Health £23.3m Posters at Cancer Immunotherapy Conference
12Sep19 15:56 RNS Scancell 0.00% Health £23.3m Result of AGM
04Sep19 07:00 RNS Scancell 0.00% Health £23.3m First Collaboration Agreement for AvidiMab
20Aug19 14:23 RNS Scancell 0.00% Health £23.3m Notice of AGM
20Aug19 07:00 RNS Scancell 0.00% Health £23.3m Final Results for the year ended 30 April 2019
19Aug19 07:00 RNS Scancell 0.00% Health £23.3m Update on the SCIB1 Phase 2 clinical trial
07Aug19 07:00 RNS Scancell 0.00% Health £23.3m Notice of Final Results
01Jul19 07:00 RNS-R Scancell 0.00% Health £23.3m H1 2019 Business Update
18Jun19 09:16 RNS Hygea VCT 0.00% Various Various Holding(s) in Company
18Jun19 07:00 RNS Scancell 0.00% Health £23.3m Board Appointment
17Jun19 10:45 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
14Jun19 16:41 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
13Jun19 07:00 RNS Scancell 0.00% Health £23.3m Share Subscription and Issue of Equity to Vulpes
29May19 11:05 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
20May19 07:00 RNS-R Scancell 0.00% Health £23.3m Scancell and CRUK provide an update on SCIB2
10May19 07:00 RNS-R Scancell 0.00% Health £23.3m Clinical Advisory Board and Update on Modi-1
25Apr19 07:00 RNS Scancell 0.00% Health £23.3m UK approval to start SCIB1 Phase 2 trial
08Apr19 07:00 RNS-R Scancell 0.00% Health £23.3m Japan patent for Moditope immunotherapy platform
21Mar19 07:00 RNS-R Scancell 0.00% Health £23.3m Professor Lindy Durrant receives Waldenström award
20Mar19 07:00 RNS Scancell 0.00% Health £23.3m Scancell strengthens IP portfolio
05Mar19 18:27 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
04Mar19 16:40 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
21Feb19 07:00 RNS Scancell 0.00% Health £23.3m Change of Auditor
31Jan19 07:00 RNS Scancell 0.00% Health £23.3m Interim Results
23Jan19 07:00 RNS-R Scancell 0.00% Health £23.3m Update on Cancer Research UK's Grand Challenge
21Jan19 07:00 RNS-R Scancell 0.00% Health £23.3m Appoints Heads of Research and Manufacturing
12Nov18 07:00 RNS-R Scancell 0.00% Health £23.3m Scancell to Present at Two Conferences
01Nov18 07:00 RNS-R Scancell 0.00% Health £23.3m Scancell to present at Proactive Investors Forum
30Oct18 17:18 RNS Scancell 0.00% Health £23.3m Results of AGM
30Oct18 07:00 RNS Scancell 0.00% Health £23.3m Identification of 2nd Moditope Cancer Vaccine
24Oct18 09:05 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
24Oct18 07:00 RNS Scancell 0.00% Health £23.3m Update on SCIB1 Phase 2 Clinical Study
05Oct18 07:00 RNS Scancell 0.00% Health £23.3m Notice of AGM
25Sep18 07:00 RNS Scancell 0.00% Health £23.3m Final Results for the year ended 30 April 2018
18Sep18 07:00 RNS Scancell 0.00% Health £23.3m Notice of Final Results
10Aug18 07:00 RNS Scancell 0.00% Health £23.3m Board Change
09Aug18 07:00 RNS Scancell 0.00% Health £23.3m Agreement
25Jul18 14:45 RNS Scancell 0.00% Health £23.3m Director/PDMR Shareholding
24Jul18 07:00 RNS Scancell 0.00% Health £23.3m Issue of Equity
18Jul18 07:00 RNS Scancell 0.00% Health £23.3m Scancell exercises TriGrid commercial option
11May18 13:11 RNS Legal & General Group 1.40% Various Various Holding(s) in Company
09May18 10:12 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
08May18 07:00 RNS Scancell 0.00% Health £23.3m Result of the Open Offer and PDMR Shareholdings
23Apr18 12:43 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
20Apr18 16:32 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
18Apr18 14:29 RNS Scancell 0.00% Health £23.3m Result of Placing and Subscription and PDMR
18Apr18 11:05 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
18Apr18 07:00 RNS Scancell 0.00% Health £23.3m Proposed Placing, Subscription and Open Offer
15Feb18 07:00 RNS Scancell 0.00% Health £23.3m Collaboration agreement with ISA Pharmaceuticals
12Feb18 07:00 RNS Scancell 0.00% Health £23.3m Publication highlights potential of SCIB1 therapy
09Feb18 07:00 RNS Scancell 0.00% Health £23.3m European patent application allowed for grant
01Feb18 07:00 RNS Scancell 0.00% Health £23.3m Director/PDMR Shareholding
30Jan18 07:00 RNS Scancell 0.00% Health £23.3m Half-year Report
09Jan18 07:00 RNS Scancell 0.00% Health £23.3m Scancell to collaborate with BioNTech
14Dec17 07:00 RNS Scancell 0.00% Health £23.3m Scancell and CRUK to advance cancer immunotherapy
11Oct17 09:44 RNS Scancell 0.00% Health £23.3m Result of AGM
10Oct17 07:00 RNS Scancell 0.00% Health £23.3m Directorate Change
14Sep17 07:00 RNS Scancell 0.00% Health £23.3m Notice of AGM
13Sep17 07:00 RNS Scancell 0.00% Health £23.3m Final Results
11Jul17 07:00 RNS Scancell 0.00% Health £23.3m Continued Progress on SCIB1
22May17 12:59 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
19May17 14:47 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
19May17 07:00 RNS Legal & General Group 1.40% Various Various Holding(s) in Company
11May17 12:09 RNS Scancell 0.00% Health £23.3m Results of Placing
11May17 07:00 RNS Scancell 0.00% Health £23.3m Proposed Placing to Raise up to £5.0 million
01Mar17 07:00 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
31Jan17 07:00 RNS Scancell 0.00% Health £23.3m Interim Results
30Jan17 07:00 RNS Scancell 0.00% Health £23.3m Partnership to Advance Lung Cancer Clinical Trials
03Jan17 11:33 RNS Scancell 0.00% Health £23.3m Research Update - Amendment
03Jan17 07:00 RNS Scancell 0.00% Health £23.3m Research Update
18Oct16 17:42 RNS Scancell 0.00% Health £23.3m Results of AGM
10Oct16 07:00 RNS Scancell 0.00% Health £23.3m Preparing SCIB2 for clinical study in lung cancer
23Sep16 17:24 RNS Scancell 0.00% Health £23.3m Notice of AGM - Amendment
23Sep16 15:28 RNS Scancell 0.00% Health £23.3m Notice of AGM
16Sep16 07:00 RNS Scancell 0.00% Health £23.3m Final Results
22Aug16 07:00 RNS Scancell 0.00% Health £23.3m Appointment of Non-Executive Director
21Jul16 07:00 RNS Scancell 0.00% Health £23.3m Eurogentec manufacturing agreement
20Jul16 07:00 RNS Scancell 0.00% Health £23.3m Extension to Ichor Commercial Option
06Jul16 07:00 RNS Scancell 0.00% Health £23.3m SCIB1 compelling survival data in melanoma
29Jun16 16:40 RNS Scancell 0.00% Health £23.3m Second Price Monitoring Extn
17Jun16 07:00 RNS Scancell 0.00% Health £23.3m SCIB1 Drug Product Supply
18May16 07:00 RNS Scancell 0.00% Health £23.3m Opens US Headquarters in San Diego
19Apr16 07:00 RNS Scancell 0.00% Health £23.3m Director/PDMR Shareholding
11Apr16 16:11 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
06Apr16 07:00 RNS Scancell 0.00% Health £23.3m Holding(s) in Company
04Apr16 10:17 RNS Scancell 0.00% Health £23.3m Result of the open offer
01Apr16 07:00 RNS Scancell 0.00% Health £23.3m Result of open offer
11Mar16 07:00 RNS Scancell 0.00% Health £23.3m Posting of Circular
11Mar16 07:00 RNS Scancell 0.00% Health £23.3m Strategic collaboration with Karolinska Institutet
09Mar16 14:07 RNS Scancell 0.00% Health £23.3m Placing and Open Offer Close
09Mar16 07:00 RNS Scancell 0.00% Health £23.3m Proposed Placing and Open Offer
Date / Time Source Company % Chg
16Mar20 16:42 RNS Scancell 0.00%
Second Price Monitoring Extn
03Mar20 07:00 RNS-R Scancell 0.00%
Scancell to Present at Three Research Conferences
03Feb20 07:00 RNS Scancell 0.00%
SCIB1 IND Application Approved
31Jan20 07:00 RNS Scancell 0.00%
Interim Results
20Jan20 07:00 RNS Scancell 0.00%
Third agreement signed for antibody platform
17Dec19 12:44 RNS Scancell 0.00%
Director's Dealings
16Dec19 07:00 RNS Scancell 0.00%
Second agreement signed for AvidiMab platform
20Nov19 07:00 RNS Scancell 0.00%
New European Moditope patent allowed for grant
23Oct19 07:00 RNS Scancell 0.00%
Directorate Change
26Sep19 07:00 RNS Scancell 0.00%
Posters at Cancer Immunotherapy Conference
12Sep19 15:56 RNS Scancell 0.00%
Result of AGM
04Sep19 07:00 RNS Scancell 0.00%
First Collaboration Agreement for AvidiMab
20Aug19 14:23 RNS Scancell 0.00%
Notice of AGM
20Aug19 07:00 RNS Scancell 0.00%
Final Results for the year ended 30 April 2019
19Aug19 07:00 RNS Scancell 0.00%
Update on the SCIB1 Phase 2 clinical trial
07Aug19 07:00 RNS Scancell 0.00%
Notice of Final Results
01Jul19 07:00 RNS-R Scancell 0.00%
H1 2019 Business Update
18Jun19 09:16 RNS Hygea VCT 0.00%
Holding(s) in Company
18Jun19 07:00 RNS Scancell 0.00%
Board Appointment
17Jun19 10:45 RNS Scancell 0.00%
Holding(s) in Company
14Jun19 16:41 RNS Scancell 0.00%
Second Price Monitoring Extn
13Jun19 07:00 RNS Scancell 0.00%
Share Subscription and Issue of Equity to Vulpes
29May19 11:05 RNS Scancell 0.00%
Second Price Monitoring Extn
20May19 07:00 RNS-R Scancell 0.00%
Scancell and CRUK provide an update on SCIB2
10May19 07:00 RNS-R Scancell 0.00%
Clinical Advisory Board and Update on Modi-1
25Apr19 07:00 RNS Scancell 0.00%
UK approval to start SCIB1 Phase 2 trial
08Apr19 07:00 RNS-R Scancell 0.00%
Japan patent for Moditope immunotherapy platform
21Mar19 07:00 RNS-R Scancell 0.00%
Professor Lindy Durrant receives Waldenström award
20Mar19 07:00 RNS Scancell 0.00%
Scancell strengthens IP portfolio
05Mar19 18:27 RNS Scancell 0.00%
Holding(s) in Company
04Mar19 16:40 RNS Scancell 0.00%
Second Price Monitoring Extn
21Feb19 07:00 RNS Scancell 0.00%
Change of Auditor
31Jan19 07:00 RNS Scancell 0.00%
Interim Results
23Jan19 07:00 RNS-R Scancell 0.00%
Update on Cancer Research UK's Grand Challenge
21Jan19 07:00 RNS-R Scancell 0.00%
Appoints Heads of Research and Manufacturing
12Nov18 07:00 RNS-R Scancell 0.00%
Scancell to Present at Two Conferences
01Nov18 07:00 RNS-R Scancell 0.00%
Scancell to present at Proactive Investors Forum
30Oct18 17:18 RNS Scancell 0.00%
Results of AGM
30Oct18 07:00 RNS Scancell 0.00%
Identification of 2nd Moditope Cancer Vaccine
24Oct18 09:05 RNS Scancell 0.00%
Second Price Monitoring Extn
24Oct18 07:00 RNS Scancell 0.00%
Update on SCIB1 Phase 2 Clinical Study
05Oct18 07:00 RNS Scancell 0.00%
Notice of AGM
25Sep18 07:00 RNS Scancell 0.00%
Final Results for the year ended 30 April 2018
18Sep18 07:00 RNS Scancell 0.00%
Notice of Final Results
10Aug18 07:00 RNS Scancell 0.00%
Board Change
09Aug18 07:00 RNS Scancell 0.00%
Agreement
25Jul18 14:45 RNS Scancell 0.00%
Director/PDMR Shareholding
24Jul18 07:00 RNS Scancell 0.00%
Issue of Equity
18Jul18 07:00 RNS Scancell 0.00%
Scancell exercises TriGrid commercial option
11May18 13:11 RNS Legal & General Group 1.40%
Holding(s) in Company
09May18 10:12 RNS Scancell 0.00%
Holding(s) in Company
08May18 07:00 RNS Scancell 0.00%
Result of the Open Offer and PDMR Shareholdings
23Apr18 12:43 RNS Scancell 0.00%
Holding(s) in Company
20Apr18 16:32 RNS Scancell 0.00%
Holding(s) in Company
18Apr18 14:29 RNS Scancell 0.00%
Result of Placing and Subscription and PDMR
18Apr18 11:05 RNS Scancell 0.00%
Second Price Monitoring Extn
18Apr18 07:00 RNS Scancell 0.00%
Proposed Placing, Subscription and Open Offer
15Feb18 07:00 RNS Scancell 0.00%
Collaboration agreement with ISA Pharmaceuticals
12Feb18 07:00 RNS Scancell 0.00%
Publication highlights potential of SCIB1 therapy
09Feb18 07:00 RNS Scancell 0.00%
European patent application allowed for grant
01Feb18 07:00 RNS Scancell 0.00%
Director/PDMR Shareholding
30Jan18 07:00 RNS Scancell 0.00%
Half-year Report
09Jan18 07:00 RNS Scancell 0.00%
Scancell to collaborate with BioNTech
14Dec17 07:00 RNS Scancell 0.00%
Scancell and CRUK to advance cancer immunotherapy
11Oct17 09:44 RNS Scancell 0.00%
Result of AGM
10Oct17 07:00 RNS Scancell 0.00%
Directorate Change
14Sep17 07:00 RNS Scancell 0.00%
Notice of AGM
13Sep17 07:00 RNS Scancell 0.00%
Final Results
11Jul17 07:00 RNS Scancell 0.00%
Continued Progress on SCIB1
22May17 12:59 RNS Scancell 0.00%
Holding(s) in Company
19May17 14:47 RNS Scancell 0.00%
Holding(s) in Company
19May17 07:00 RNS Legal & General Group 1.40%
Holding(s) in Company
11May17 12:09 RNS Scancell 0.00%
Results of Placing
11May17 07:00 RNS Scancell 0.00%
Proposed Placing to Raise up to £5.0 million
01Mar17 07:00 RNS Scancell 0.00%
Holding(s) in Company
31Jan17 07:00 RNS Scancell 0.00%
Interim Results
30Jan17 07:00 RNS Scancell 0.00%
Partnership to Advance Lung Cancer Clinical Trials
03Jan17 11:33 RNS Scancell 0.00%
Research Update - Amendment
03Jan17 07:00 RNS Scancell 0.00%
Research Update
18Oct16 17:42 RNS Scancell 0.00%
Results of AGM
10Oct16 07:00 RNS Scancell 0.00%
Preparing SCIB2 for clinical study in lung cancer
23Sep16 17:24 RNS Scancell 0.00%
Notice of AGM - Amendment
23Sep16 15:28 RNS Scancell 0.00%
Notice of AGM
16Sep16 07:00 RNS Scancell 0.00%
Final Results
22Aug16 07:00 RNS Scancell 0.00%
Appointment of Non-Executive Director
21Jul16 07:00 RNS Scancell 0.00%
Eurogentec manufacturing agreement
20Jul16 07:00 RNS Scancell 0.00%
Extension to Ichor Commercial Option
06Jul16 07:00 RNS Scancell 0.00%
SCIB1 compelling survival data in melanoma
29Jun16 16:40 RNS Scancell 0.00%
Second Price Monitoring Extn
17Jun16 07:00 RNS Scancell 0.00%
SCIB1 Drug Product Supply
18May16 07:00 RNS Scancell 0.00%
Opens US Headquarters in San Diego
19Apr16 07:00 RNS Scancell 0.00%
Director/PDMR Shareholding
11Apr16 16:11 RNS Scancell 0.00%
Holding(s) in Company
06Apr16 07:00 RNS Scancell 0.00%
Holding(s) in Company
04Apr16 10:17 RNS Scancell 0.00%
Result of the open offer
01Apr16 07:00 RNS Scancell 0.00%
Result of open offer
11Mar16 07:00 RNS Scancell 0.00%
Posting of Circular
11Mar16 07:00 RNS Scancell 0.00%
Strategic collaboration with Karolinska Institutet
09Mar16 14:07 RNS Scancell 0.00%
Placing and Open Offer Close
09Mar16 07:00 RNS Scancell 0.00%
Proposed Placing and Open Offer
Date / Time Company % Chg
16Mar20 16:42 Scancell 0.00%
Second Price Monitoring Extn
03Mar20 07:00 Scancell 0.00%
Scancell to Present at Three Research Conferences
03Feb20 07:00 Scancell 0.00%
SCIB1 IND Application Approved
31Jan20 07:00 Scancell 0.00%
Interim Results
20Jan20 07:00 Scancell 0.00%
Third agreement signed for antibody platform
17Dec19 12:44 Scancell 0.00%
Director's Dealings
16Dec19 07:00 Scancell 0.00%
Second agreement signed for AvidiMab platform
20Nov19 07:00 Scancell 0.00%
New European Moditope patent allowed for grant
23Oct19 07:00 Scancell 0.00%
Directorate Change
26Sep19 07:00 Scancell 0.00%
Posters at Cancer Immunotherapy Conference
12Sep19 15:56 Scancell 0.00%
Result of AGM
04Sep19 07:00 Scancell 0.00%
First Collaboration Agreement for AvidiMab
20Aug19 14:23 Scancell 0.00%
Notice of AGM
20Aug19 07:00 Scancell 0.00%
Final Results for the year ended 30 April 2019
19Aug19 07:00 Scancell 0.00%
Update on the SCIB1 Phase 2 clinical trial
07Aug19 07:00 Scancell 0.00%
Notice of Final Results
01Jul19 07:00 Scancell 0.00%
H1 2019 Business Update
18Jun19 09:16 HYG LSE,SCLP LSE 0.00%
Holding(s) in Company
18Jun19 07:00 Scancell 0.00%
Board Appointment
17Jun19 10:45 Scancell 0.00%
Holding(s) in Company
14Jun19 16:41 Scancell 0.00%
Second Price Monitoring Extn
13Jun19 07:00 Scancell 0.00%
Share Subscription and Issue of Equity to Vulpes
29May19 11:05 Scancell 0.00%
Second Price Monitoring Extn
20May19 07:00 Scancell 0.00%
Scancell and CRUK provide an update on SCIB2
10May19 07:00 Scancell 0.00%
Clinical Advisory Board and Update on Modi-1
25Apr19 07:00 Scancell 0.00%
UK approval to start SCIB1 Phase 2 trial
08Apr19 07:00 Scancell 0.00%
Japan patent for Moditope immunotherapy platform
21Mar19 07:00 Scancell 0.00%
Professor Lindy Durrant receives Waldenström award
20Mar19 07:00 Scancell 0.00%
Scancell strengthens IP portfolio
05Mar19 18:27 Scancell 0.00%
Holding(s) in Company
04Mar19 16:40 Scancell 0.00%
Second Price Monitoring Extn
21Feb19 07:00 Scancell 0.00%
Change of Auditor
31Jan19 07:00 Scancell 0.00%
Interim Results
23Jan19 07:00 Scancell 0.00%
Update on Cancer Research UK's Grand Challenge
21Jan19 07:00 Scancell 0.00%
Appoints Heads of Research and Manufacturing
12Nov18 07:00 Scancell 0.00%
Scancell to Present at Two Conferences
01Nov18 07:00 Scancell 0.00%
Scancell to present at Proactive Investors Forum
30Oct18 17:18 Scancell 0.00%
Results of AGM
30Oct18 07:00 Scancell 0.00%
Identification of 2nd Moditope Cancer Vaccine
24Oct18 09:05 Scancell 0.00%
Second Price Monitoring Extn
24Oct18 07:00 Scancell 0.00%
Update on SCIB1 Phase 2 Clinical Study
05Oct18 07:00 Scancell 0.00%
Notice of AGM
25Sep18 07:00 Scancell 0.00%
Final Results for the year ended 30 April 2018
18Sep18 07:00 Scancell 0.00%
Notice of Final Results
10Aug18 07:00 Scancell 0.00%
Board Change
09Aug18 07:00 Scancell 0.00%
Agreement
25Jul18 14:45 Scancell 0.00%
Director/PDMR Shareholding
24Jul18 07:00 Scancell 0.00%
Issue of Equity
18Jul18 07:00 Scancell 0.00%
Scancell exercises TriGrid commercial option
11May18 13:11 LGEN LSE,SCLP LSE 1.40%
Holding(s) in Company
09May18 10:12 Scancell 0.00%
Holding(s) in Company
08May18 07:00 Scancell 0.00%
Result of the Open Offer and PDMR Shareholdings
23Apr18 12:43 Scancell 0.00%
Holding(s) in Company
20Apr18 16:32 Scancell 0.00%
Holding(s) in Company
18Apr18 14:29 Scancell 0.00%
Result of Placing and Subscription and PDMR
18Apr18 11:05 Scancell 0.00%
Second Price Monitoring Extn
18Apr18 07:00 Scancell 0.00%
Proposed Placing, Subscription and Open Offer
15Feb18 07:00 Scancell 0.00%
Collaboration agreement with ISA Pharmaceuticals
12Feb18 07:00 Scancell 0.00%
Publication highlights potential of SCIB1 therapy
09Feb18 07:00 Scancell 0.00%
European patent application allowed for grant
01Feb18 07:00 Scancell 0.00%
Director/PDMR Shareholding
30Jan18 07:00 Scancell 0.00%
Half-year Report
09Jan18 07:00 Scancell 0.00%
Scancell to collaborate with BioNTech
14Dec17 07:00 Scancell 0.00%
Scancell and CRUK to advance cancer immunotherapy
11Oct17 09:44 Scancell 0.00%
Result of AGM
10Oct17 07:00 Scancell 0.00%
Directorate Change
14Sep17 07:00 Scancell 0.00%
Notice of AGM
13Sep17 07:00 Scancell 0.00%
Final Results
11Jul17 07:00 Scancell 0.00%
Continued Progress on SCIB1
22May17 12:59 Scancell 0.00%
Holding(s) in Company
19May17 14:47 Scancell 0.00%
Holding(s) in Company
19May17 07:00 LGEN LSE,SCLP LSE 1.40%
Holding(s) in Company
11May17 12:09 Scancell 0.00%
Results of Placing
11May17 07:00 Scancell 0.00%
Proposed Placing to Raise up to £5.0 million
01Mar17 07:00 Scancell 0.00%
Holding(s) in Company
31Jan17 07:00 Scancell 0.00%
Interim Results
30Jan17 07:00 Scancell 0.00%
Partnership to Advance Lung Cancer Clinical Trials
03Jan17 11:33 Scancell 0.00%
Research Update - Amendment
03Jan17 07:00 Scancell 0.00%
Research Update
18Oct16 17:42 Scancell 0.00%
Results of AGM
10Oct16 07:00 Scancell 0.00%
Preparing SCIB2 for clinical study in lung cancer
23Sep16 17:24 Scancell 0.00%
Notice of AGM - Amendment
23Sep16 15:28 Scancell 0.00%
Notice of AGM
16Sep16 07:00 Scancell 0.00%
Final Results
22Aug16 07:00 Scancell 0.00%
Appointment of Non-Executive Director
21Jul16 07:00 Scancell 0.00%
Eurogentec manufacturing agreement
20Jul16 07:00 Scancell 0.00%
Extension to Ichor Commercial Option
06Jul16 07:00 Scancell 0.00%
SCIB1 compelling survival data in melanoma
29Jun16 16:40 Scancell 0.00%
Second Price Monitoring Extn
17Jun16 07:00 Scancell 0.00%
SCIB1 Drug Product Supply
18May16 07:00 Scancell 0.00%
Opens US Headquarters in San Diego
19Apr16 07:00 Scancell 0.00%
Director/PDMR Shareholding
11Apr16 16:11 Scancell 0.00%
Holding(s) in Company
06Apr16 07:00 Scancell 0.00%
Holding(s) in Company
04Apr16 10:17 Scancell 0.00%
Result of the open offer
01Apr16 07:00 Scancell 0.00%
Result of open offer
11Mar16 07:00 Scancell 0.00%
Posting of Circular
11Mar16 07:00 Scancell 0.00%
Strategic collaboration with Karolinska Institutet
09Mar16 14:07 Scancell 0.00%
Placing and Open Offer Close
09Mar16 07:00 Scancell 0.00%
Proposed Placing and Open Offer